Hepatymo 300mg treatment for chronic hepatitis B (3 blisters x 10 tablets)

Dosage form Box of 3 blisters x 10 tablets
Specifications Tenofovir disoproxil fumarat

Ingredient

Composition information	Content
Tenofovir disoproxil fumarat	300mg

Uses

Indications

Hepatymo 300mg is indicated in the following cases:

Chronic hepatitis B in adults with liver disease is still compensated and there is evidence of virus copying and histological evidence of active inflammation or fibrosis. The structure of a nucleotid diester similar to adenosin monophosphate, is a precursor of Tenofovir. After being phosphoryl turned into an active diphosphate form, Tenofovir Diphosphate is resistant to HBV's polymerase and the background of HIV.

Tenofovir diphosphate inhibits the polymerase of the virus (reverse code star) by competing directly with the natural substrate Deoxyribonucleotid and ends the DNA chain after attaching to the DNA chain of the virus.

pharmacokinetic

absorption

Tenofovir disoproxil fumarat is absorbed and converted into fast tenofovir after drinking, with peak concentrations after 1-2 hours. Birth in dieters is about 25% but increases when drinking at a high fat meal.

Distribution

Tenofovir is widely distributed throughout the body tissue, especially the kidney and liver. Tenofovir is linked to plasma proteins below 1% and with serum protein about 7%.

Metabolism

Tenofovir disoproxil fumarat is absorbed and converted into tenofovir.

Elimination

Tenofovir waste sale time is 12 - 18 hours. Elimination mainly through urine.

Before taking Hepatymo 300mg treatment for chronic hepatitis B (3 blisters x 10 tablets)

How to use

Take oral use.

Dosage

Adults

HIV infection treatment:

1 tablet x 1 time/day, combined with other antiviral drugs.

HIV infection:

1 tablet x 1 time/day in combination with other antiviral drugs. The provision should start as soon as possible after contact (preferably within a few hours than a few days) and continue for the next 4 weeks if tolerated.

Treatment of chronic hepatitis B:

recommended dose is 1 tablet 1 time/day for more than 48 weeks.

Patients with renal failure

Should reduce the dose by adjusting the duration of the drug duration in patients with renal impairment based on the clearine clearance (CICR) of the patient:

CLCR> 50ml/minute: Use the usual doses 1 time/day.

For patients with impaired liver function, the dose is not required.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.

What to do when overdose?

Symptoms

Nausea, vomiting, skin rash, lower blood phosphate levels, acute renal failure, lactic acid poisoning.

Handling

Symptomatic treatment and support. Can use hematopathy to type tenofovir.

What to do when you forget a dose? However, if close to the next dose, skip the forgotten dose and take the next dose at the time as planned. Note that it should not be used double the prescribed dose.

Side Effects

When using Hepatymo 300mg, you may experience unwanted effects (ADR).

Common

Digestive: diarrhea, nausea, abdominal pain, indigestion, flatulence and anorexia.

Increased serum amylase, pancreatitis.

Lower blood phosphate.

skin rash.

Other effects such as peripheral neuropathy, headache, dizziness, insomnia, depression, weakness, sweating, muscle pain.

There has been a report on hyper enzyme, hypereminemia, hyperglycemia and neutropenia. Kidney failure, acute renal failure and effects on renal tubules, including fanconi syndrome ..

Instructions on how to handle ADR

When experiencing side effects of the drug, it is necessary to stop using and notify the doctor or go to the nearest medical facility for timely treatment.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

Hepatymo 300mg contraindicated drug in the case of patients sensitive to tenofovir or any ingredients of the drug.

Precautions when using

Monitor the concentration of ALT & HBV DNA serum after stopping treatment.

Stop treatment if contaminated with lactic acid, serious liver with fatty and after treatment of severe hepatitis.

Should not be used in patients with galactose intolerance, lactase lactase or poor absorption of glucose-galactose.

The elderly, patients are at risk of renal dysfunction, cirrhosis, HIV -infected and hepatitis B, fuzzy metabolic disorders, have signs of bone abnormalities, a history of joint pain and stiffness, difficulty movement.

The ability to drive and operate machinery

There is no report. Usually not affected.

Pregnancy

There is no full range of verification studies in pregnant women, so only use drugs when really necessary.

Breastfeeding period

Not yet determined whether the drug is excreted by breast milk, so do not breastfeed when taking the drug.

Drug interaction

should not coordinate Tenofovir Disoproxil Fumarat with: Didanosine, Atazanavir, Tacrolimus and drugs that reduce or compete for renal excretion or competition.

Patients with HIV/HBV co -infected patients should combine Retrovirus resistance and appropriate diet.

Storage

In a dry place, the temperature does not exceed 30 ° C, avoiding light.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.